# Asundexian versus Apixaban in Patients with Atrial Fibrillation

*PRI Rank #7 · Topics and Trends in Most Cited Atrial Fibrillation Management and Outcomes Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/atrial-fibrillation-management-and-outcomes/2026/rank-7*

| Field | Value |
| --- | --- |
| Rank | #7 |
| 18m citations | 118 |
| Journal | New England Journal of Medicine |
| Year | 2024 |
| DOI | 10.1056/nejmoa2407105 |
| Corresponding authors | Jonathan P Piccini |
| Institution | Duke Clinical Research Institute, United States |

**Ranking page:** [Topics and Trends in Most Cited Atrial Fibrillation Management and Outcomes Papers, Class of 2026](https://pri.pepkio.com/top-papers/atrial-fibrillation-management-and-outcomes/2026)

**Paper link:** [10.1056/nejmoa2407105](https://doi.org/10.1056/nejmoa2407105)

## Topics

Factor XI inhibition · Apixaban · Factor XI inhibition · Direct oral anticoagulants · atrial fibrillation · Stroke prevention · Thromboembolic events · Major bleeding · CHA2DS2-VASc score · Noninferiority trial · Early trial termination · Data and safety monitoring board · OCEANIC-AF trial · phase 3 trial · Factor XI inhibition · Hazard ratio · Bleeding risk assessment

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Atrial Fibrillation Management and Outcomes Papers, Class of 2026. https://pri.pepkio.com/top-papers/atrial-fibrillation-management-and-outcomes/2026. Accessed 2026-07-14.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```